Trials / Recruiting
RecruitingNCT06404840
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases (PCLM): A Prospective, Single-Arm, Phase II Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Patients with PCLM account for the majority of our department's pancreatic cancer cases and often have limited surgical options due to the aggressive nature of their tumors. For those with good performance status (ECOG PS 0-1), NCCN recommends gemcitabine + nab-paclitaxel (AG). Though nimotuzumab combined with gemcitabine improves survival, there remains scarce clinical data regarding its efficacy in conjunction with AG for treating PCLM. This study aims to evaluate the safety and efficacy of incorporating nimotuzumab with AG for PCLM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nimotuzumab | nimotuzumab (400 mg, iv, d1, qw) |
| DRUG | AG chemotherapy | (gemcitabine 1000mg/m², Nab-paclitaxel 125mg/m², d1, d8, 21d cycle) |
Timeline
- Start date
- 2022-05-06
- Primary completion
- 2025-03-31
- Completion
- 2026-05-31
- First posted
- 2024-05-08
- Last updated
- 2024-05-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06404840. Inclusion in this directory is not an endorsement.